1. Talphera will announce Q1 2025 financial results on May 14. 2. A live webcast and call will follow the financial release. 3. Talphera's lead product, Niyad™, has FDA Breakthrough Device Designation. 4. Niyad™ is studied as an anticoagulant for medical settings. 5. The event is crucial for investor insights into future performance.
The upcoming financial results and product designation could positively influence investor sentiment, as seen in similar events in the past where companies with breakthrough designations often see a rise in stock prices ahead of earnings announcements.
The combination of a financial result announcement and the Breakthrough Device Designation creates significant investor interest, which could lead to price volatility based on the outcome and subsequent market reaction.
The financial results and webcast are immediate catalysts that can influence stock prices quickly, similar to past earnings announcements leading to rapid price changes.
/PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 58894.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.